Pharmaceutical company Eris Lifesciences reported a 41 percent on-year (YoY) increase in its consolidated net profit for the first quarter of fiscal year 2026 at Rs 125 crore, a company filing said on August 5, driven by strong performance in its domestic branded formulations (DBF) business and improved operating margins.
The company’s consolidated revenue rose 7.4% YoY to ₹773 crore, while EBITDA grew 11% YoY to ₹277 crore, with margins expanding by 106 basis points to 35.8%. The DBF segment outperformed the Indian pharmaceutical market (IPM), growing 11% YoY, and its operating margin improved by 155 bps to 37% supported by the addition of over 300 medical representatives and improved product mix. Twelve of Eris’ top 25 mother brands now rank among the top five in their respective categories, with five brands crossing ₹100 crore in annual revenue.
The profit growth was further supported by a 20% reduction in finance costs due to accelerated debt repayment. Eris also reported strategic progress in its insulin and GLP-1 portfolios, with manufacturing ramp-ups and new product validations underway.
The company has a net debt of Rs 2,317 crore as on June 30, 2025.
“Our domestic branded formulations business has delivered a yoy growth of 11% which is over 40% ahead of market growth," said . Amit Bakshi, Chairman & Managing Director of Eris said.
"Our thesis of reorienting our DBF portfolio to high-growth segments has started delivering results. We are well positioned to ensure continuity of supply in the RHI Penfill segment given the exit of the innovator. Our GLP-1 go-to-market is shaping up as planned and we expect to be among the first players in the market post LoE,” he added.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
